Why partner with EVA Pharma?
EVA Pharma is a partnership-driven pharmaceutical company with EU, US, and GCC-approved manufacturing facilities. We produce a wide range of branded generics (solids, injectables, eye drops, patches, liquids, and creams) and have a strong regional sales and marketing network. Our portfolio includes 300+ marketed products and 500+ in development. This strong manufacturing infrastructure is then armed with a solid marketing, promotion, and distribution network that spans the region. EVA Pharma also has a notable collection of EU-CTD dossier available.
Our Clusters
Egypt Cluster
GCC & Algeria cluster
Sub-Sahara Africa cluster
Our Strategic Alliances
EVA Pharma and Lilly's partnership has led to significant milestones to begin distribution of the African-made insulin products and to reach one million people per year by 2030. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited -resource settings, annually, by 2030. Another achieved milestone in this collaboration is the launch of Verzenio in Egypt as part of the "100 Million Health" initiative, aiming to treat over 20,000 breast cancer patients annually. These achievements underscore the effectiveness of their collaboration in expanding healthcare access and delivering essential treatments across key regions.
In-Licensing
We focus on highly differentiated and innovative products to complement our portfolio, we are open to different business models including licensing of FDF and/or Bulk with supply, in addition to Tech transfer Our areas of focus are : .Biosimilars .mRNA technology .Small molecules with focus on oncology products and hormones .Vaccines with focus on epidemic diseases, Flu and Covid
10 In-Licensed products
9 Oncology small molecules
1 Biosimilar
5 Partners
bioventure, ADALVO, TENCIMEDE, synchrony ,bluepharma
9 Products in Tenders
3 products are Reimbursed in UPA (Biggest Governmental Tender in Egypt)
3 products submitted in NUPCO (Biggest KSA Tender)
3 products submitted in in RAFED (UAE Tender)
7 Registered Products in Egypt, UAE, KSA.
Granting MAs for Gefitinib, Bicalutamide, Zoledronic Acid, Lenalidomide, Temozolomide, Abiraterone and Adalimumab
Out-Licensing
We offer a product list of more than 35 products in EU CTD format including differentiated dosage forms like DPIs, Transdermal Patches, in addition to solid dosage forms, injectables, and eye drops. Through the past few years, we developed B2B partnerships with 37 global partners inthe EU, UK, Canada & latin America, who granted MAs and launched the products in more than 29 EU countries. Our products lies in different therapeutic areas including Antiemetics, Anti-infectives, Cardiovascular, Diabetes, Neurology, Ophthalmology, Pain, Respiratory, Rheumatology, Urology, and Andrology.
46 Out-licensing partnerships in 29 EU countries
37 Global partners in the EU, UK, Canada & latin America
CDMO
Since EVA Pharma has more than 100 years experience in different dosage forms including tablets, hard and soft gelatin capsules, sachets, DPI, ampoules, vials, ophthalmic and sterile cephalosporins, we offer CDMO services with very competitive prices using our dedicated pilot area. Our experience has led us to have : more than 300 products in market, more than 500 products in pipeline & more than 200 scientists specialized in various dosage forms
6 Products in CDMO
CMO
EVA Pharma is recognized as reliable, flexible, high quality with cost effective manufacturing organization, that led to establishing a good relationship with different customers in different territories.
52 Products in the CMO portfolio
22 CMO products in technical transfer
25 Approved CMO products
Thanks for your interest in EVA Pharma
Fill up the form and our team will get back to you shortly
Follow Us
